Uscom Limited
ABN 35 091 028 090
Suite 1, Level 7, 10 Loftus Street
Sydney NSW 2000 Australia
T +612 9247 4144 F +612 9247 8157
www.uscom.com.au

MARKET ANNOUNCEMENT

USCOM: New Paediatric Publications in Sepsis and Emergency Care

Wednesday 3rd of July 2013: Uscom (ASX code: UCM).

Uscom Limited today announced the publication of two new papers published in the field of paediatrics from four world leading centres in London and Canada on studies of USCOM in paediatric sepsis and paediatric emergency medicine.

The London study was a collaboration between authors from the paediatric intensive care units at Kings College Hospital, London, and the Great Ormond St Hospital for Children, London. The study was conducted over 36months in the Kings College Hospital Intensive Care Unit and demonstrated that the serial use of USCOM to identify different haemodynamic patterns in paediatric sepsis improved clinical management of children. This study forms the foundation for a large scale, global multi-centre randomized controlled trial to establish new global practice management protocols for sepsis in children based on USCOM.

The Canadian study was a collaboration between authors from The University of Ottowa, Canada and McMasters University in Ontario, Canada. They evaluated the utility of USCOM in the demanding pediatric medical emergency team setting with the USCOM device operated by physicians and non physicians in acutely ill children. The study concluded that USCOM is applicable in this setting and could be used to identify therapeutic goals for more effective management of critically ill children.

Executive Chairman of Uscom, Rob Phillips said, *"These world leading centres have been using USCOM in clinical practice for a number of years and progressively working to define it's role as best practice in the management of children; this is the time consuming and thorough process of medical adoption. These studies provide further evidence that USCOM is being adopted as the gold standard cardiac monitor in paediatrics, particularly for best management of sepsis and septic shock in children."*

USCOM also has proven applications in management of adult sepsis and septic shock with recent publication of the Smith Madigan Inotropy Index and the BUSH protocol results in Australia demonstrating significant improvements in mortality and cost of management using USCOM guided haemoydnamic management.

References:

1. Deep A, Goonasekera CDA, Wang Y, Brierley J. Evolution of haemodynamics and outcome of fluid refractory septic shick in children. Int Care Med 2013 DOI 10.1007/s00134-013-3003-z.
2. Zorko DJ, Choong K, Gilleland J, Agar B, Baker S, Brennan C, Pullenayegum E. Urgent Ultrasound Guided Hemodynamic Assessments by a Pediatric Medical Emergency Team: A Pilot Study. PLoS ONE 2013; 8(6): e66951. doi:10.1371/journal.pone.0066951.
3. http://news.csu.edu.au/director/latestnews.cfm?itemID=97F52E7F9D01FC6CD24745BEE313C18C

Uscom Limited
ABN 35 091 028 090
Suite 1, Level 7, 10 Loftus Street
Sydney NSW 2000 Australia
T +612 9247 4144 F +612 9247 8157
www.uscom.com.au

MARKET ANNOUNCEMENT

About Uscom

Uscom Limited is an ASX listed cardiovascular medical device company (UCM). Uscom manufactures and markets a Non Invasive Ultrasonic Cardiac Output Monitor, the USCOM 1A, and a Central Blood Pressure Monitor, the BP+. The devices have global regulatory approval and USCOM is currently marketed in North America, South America, Europe, the Middle East, Australia & New Zealand, China and SE Asia.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency and Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

The Uscom BP+ technology provides simple to use, and highly accurate & repeatable measurement of central blood pressure, measuring both brachial & Central blood pressure waveforms quickly, consistently and simply using noninvasive suprasystolic oscillometry combined with a familiar upper arm cuff. The BP+ is simple to use and requires no complex training to provide reliable measurement of Augmentation Index and Arterial stiffness, pulse rate variability and signal quality indices. For more information, please visit: www.uscom.com.au, www.pulsecor.com

Uscom Contacts

Rob Phillips
Executive Chairman
rob@uscom.com.au

Sarah Prince
Company Secretary
secretary@uscom.com.au